CA3019026A1 - Fused pentacyclic imidazole derivatives as modulators of tnf activity - Google Patents
Fused pentacyclic imidazole derivatives as modulators of tnf activity Download PDFInfo
- Publication number
- CA3019026A1 CA3019026A1 CA3019026A CA3019026A CA3019026A1 CA 3019026 A1 CA3019026 A1 CA 3019026A1 CA 3019026 A CA3019026 A CA 3019026A CA 3019026 A CA3019026 A CA 3019026A CA 3019026 A1 CA3019026 A1 CA 3019026A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- formula
- optionally substituted
- heteroaryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163571.9 | 2016-04-01 | ||
| EP16163571 | 2016-04-01 | ||
| PCT/EP2017/057765 WO2017167993A1 (en) | 2016-04-01 | 2017-03-31 | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3019026A1 true CA3019026A1 (en) | 2017-10-05 |
Family
ID=55650321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3019026A Abandoned CA3019026A1 (en) | 2016-04-01 | 2017-03-31 | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10669286B2 (OSRAM) |
| EP (1) | EP3436459B1 (OSRAM) |
| JP (1) | JP6968092B2 (OSRAM) |
| CN (1) | CN109195969B (OSRAM) |
| BR (1) | BR112018069936A2 (OSRAM) |
| CA (1) | CA3019026A1 (OSRAM) |
| EA (1) | EA201892153A1 (OSRAM) |
| WO (1) | WO2017167993A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| TW201718536A (zh) | 2015-08-03 | 2017-06-01 | 必治妥美雅史谷比公司 | 可作為TNFα調節劑之雜環化合物 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN108948034B (zh) * | 2018-06-05 | 2019-09-13 | 河南大学 | 一种色满桥环异吲哚酮及其制备方法 |
| ES2951837T3 (es) * | 2018-10-24 | 2023-10-25 | UCB Biopharma SRL | Derivados de imidazol pentacíclicos condensados como moduladores de la actividad de TNF |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| TW202513567A (zh) * | 2023-06-09 | 2025-04-01 | 大陸商上海翰森生物醫藥科技有限公司 | 五環類衍生物抑制劑、其製備方法與應用 |
| TW202521544A (zh) | 2023-08-16 | 2025-06-01 | 美商雷瑟拉股份有限公司 | TNFα活性調節劑及其用途 |
| WO2025212627A1 (en) * | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025218735A1 (zh) * | 2024-04-17 | 2025-10-23 | 上海翰森生物医药科技有限公司 | 五环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004087720A1 (en) | 2003-03-10 | 2004-10-14 | Pfizer Inc. | Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1) |
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| TWI554515B (zh) | 2011-06-20 | 2016-10-21 | 維泰克斯製藥公司 | 旋轉酶(gyrase)及拓樸異構酶抑制劑之磷酸酯 |
| TR201807207T4 (tr) * | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| CN104619709B (zh) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CR20170167A (es) | 2014-10-03 | 2017-08-10 | Sanofi Sa | Derivados de imidazol pentacíclicos fusionados |
-
2017
- 2017-03-31 EP EP17714783.2A patent/EP3436459B1/en active Active
- 2017-03-31 WO PCT/EP2017/057765 patent/WO2017167993A1/en not_active Ceased
- 2017-03-31 BR BR112018069936A patent/BR112018069936A2/pt not_active Application Discontinuation
- 2017-03-31 CA CA3019026A patent/CA3019026A1/en not_active Abandoned
- 2017-03-31 JP JP2018551351A patent/JP6968092B2/ja active Active
- 2017-03-31 CN CN201780033199.XA patent/CN109195969B/zh not_active Expired - Fee Related
- 2017-03-31 EA EA201892153A patent/EA201892153A1/ru unknown
- 2017-03-31 US US16/086,418 patent/US10669286B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109195969B (zh) | 2021-12-21 |
| US20190119302A1 (en) | 2019-04-25 |
| WO2017167993A1 (en) | 2017-10-05 |
| US10669286B2 (en) | 2020-06-02 |
| EP3436459B1 (en) | 2021-08-25 |
| EP3436459A1 (en) | 2019-02-06 |
| JP6968092B2 (ja) | 2021-11-17 |
| EA201892153A1 (ru) | 2019-04-30 |
| BR112018069936A2 (pt) | 2019-02-05 |
| JP2019512535A (ja) | 2019-05-16 |
| CN109195969A (zh) | 2019-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10669286B2 (en) | Fused pentacyclic imidazole derivatives as modulators of TNF activity | |
| US9920052B2 (en) | Imidazopyridine derivatives as modulators of TNF activity | |
| US10766906B2 (en) | Fused hexacyclic imidazole derivatives as modulators of TNF activity | |
| US9890154B2 (en) | Imidazopyridine derivatives as modulators of TNF activity | |
| JP7121033B2 (ja) | Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体 | |
| CA2931019A1 (en) | Imidazopyrimidine derivatives as modulators of tnf activity | |
| CA2930866A1 (en) | Imidazotriazine derivatives as modulators of tnf activity | |
| US10654861B2 (en) | Fused pentacyclic imidazole derivatives as modulators of TNF activity | |
| CA2931581A1 (en) | Purine derivatives as modulators of tnf activity | |
| US9834553B2 (en) | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | |
| EP3303337A1 (en) | Fused tricyclic imidazo pyrazines as modulators of tnf activity | |
| CA3018907A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| CA3055863C (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211210 |
|
| EEER | Examination request |
Effective date: 20211210 |
|
| EEER | Examination request |
Effective date: 20211210 |
|
| EEER | Examination request |
Effective date: 20211210 |
|
| FZDE | Discontinued |
Effective date: 20240417 |